DBVT
DBV TechnologiesNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.23B
P/E Ratio
—
EPS
$-5.25
Beta
-0.20
52W High
$26.18
52W Low
$7.53
50-Day MA
$20.89
200-Day MA
$16.02
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, France.
Fundamentals
| Revenue (TTM) | $5.64M |
| Gross Profit (TTM) | $5.64M |
| EBITDA | $-143.86M |
| Operating Margin | -6985.00% |
| Return on Equity | -149.80% |
| Return on Assets | -61.40% |
| Revenue/Share (TTM) | $0.20 |
| Book Value | $3.58 |
| Price-to-Book | 7.15 |
| Price-to-Sales (TTM) | 218.42 |
| EV/Revenue | 24.3 |
| EV/EBITDA | -2.07 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 26.20% |
| Shares Outstanding | $59.18M |
| Float | $165.99M |
| % Insiders | 0.00% |
| % Institutions | 5.84% |
Historical Volatility
HV 10-Day
46.26%
HV 20-Day
51.82%
HV 30-Day
52.26%
HV 60-Day
64.85%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($40.10 target)
1
Strong Buy4
Buy1
SellData last updated: 4/29/2026